|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,150.90 INR | -0.62% |
|
-3.87% | -14.47% |
| 13/02 | Jefferies Adjusts Concord Biotech's Price Target to INR1,170 From INR1,290, Keeps at Hold | MT |
| 12/02 | Concord Biotech Limited, Q3 2026 Earnings Call, Feb 12, 2026 |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||
Manufacturing and trading in pharmaceutical products | 616.4Cr | 712.93Cr | 853.17Cr | 1.02TCr | 1.2TCr | |
Total Assets | 1.18TCr | 1.31TCr | 1.51TCr | 1.7TCr | 2.03TCr | |
Interest Expense | -52.32L | -5.48Cr | -4.51Cr | -2.55Cr | -52.93L | |
Income Tax Expense | 78Cr | 63Cr | 82Cr | 104.46Cr | 122.91Cr | |
CAPEX | -204.42Cr | -155.5Cr | -145.08Cr | -86Cr | -111.17Cr | |
EBT | 312.72Cr | 237.52Cr | 322.01Cr | 412.56Cr | 494.55Cr | |
D&A | 27Cr | 50Cr | 54Cr | 54Cr | 54Cr | |
Net Income | 234.89Cr | 174.93Cr | 240.09Cr | 308.1Cr | 371.64Cr |
Geographical Revenue Distribution History
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
India | 252.65Cr | 337.41Cr | 432.13Cr | 534.21Cr | 661.83Cr | |
Total Assets | 572.26Cr | 677.38Cr | 773.3Cr | 794.78Cr | 875.93Cr | |
Others | 204.5Cr | 244.07Cr | 273.78Cr | 374.75Cr | 400.28Cr | |
Total Assets | 36.57L | - | - | 2.06Cr | 66.52L | |
America | 159.25Cr | 131.45Cr | 147.25Cr | 107.98Cr | 137.97Cr |
- Stock Market
- Equities
- CONCORDBIO Stock
- Financials Concord Biotech Limited
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition